May 2026 in “Reviews in Endocrine and Metabolic Disorders” This review explores weight loss interventions during gestation, emphasizing incretin-based therapies' potential to enhance reproductive health and address metabolic changes for better maternal and fetal outcomes.
July 2023 in “Journal of Clinical Medicine” This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
2 citations
,
January 2025 in “Cutis” This review examined the dermatologic side effects and potential treatments benefits of metformin and GLP-1/GIP agonists in managing skin conditions related to hormonal and immune effects in individuals with type 2 diabetes who are overweight or obese.
June 2026 in “Dermatology and Therapy” In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.